Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Do I qualify for a cancer clinical trial?

2.

Short-course radiation matches standard therapy for endometrial cancer

3.

One-third of childhood cancer survivors experience significant fear that it could come back, study reveals

4.

Let's Talk Breast Density; Cancer, Movies, and Music; Treatment-Induced Aging?

5.

Eight Doctors Killed in Brazil's Horrifying Plane Crash


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot